Gallium Ga 68 FAPi-46 for Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, CAProstate Cancer+2 MoreGallium Ga 68 FAPi-46 - Other
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

This trial is testing a new imaging technique to see if it can detect prostate cancer. The technique uses a tracer called 68Ga-FAPi-46 which is taken up by some cancer cells. If successful, this technique could provide additional information about various types of cancer in the future.

Eligible Conditions
  • Prostate Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Up to date of surgery (range 1-60 days)

60 minutes after tracer injection
To assess the 68Ga-FAPI-46 biodistribution correlation with 68Ga-PSMA-11 PET imaging
To define and document the biodistribution of gallium 68Ga-FAPi-46 in normal and cancer tissues of patients with prostate cancer
Day 60
Malignant Neoplasms

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Basic Science (68Ga-FAPi-46 PET/CT)
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Gallium Ga 68 FAPi-46 · No Placebo Group · Phase 1

Basic Science (68Ga-FAPi-46 PET/CT)Experimental Group · 3 Interventions: Gallium Ga 68 FAPi-46, Computed Tomography, Positron Emission Tomography · Intervention Types: Other, Procedure, Procedure
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Computed Tomography
2017
Completed Phase 2
~3410
Positron Emission Tomography
2008
Completed Phase 2
~2800

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to date of surgery (range 1-60 days)

Who is running the clinical trial?

Jonsson Comprehensive Cancer CenterLead Sponsor
341 Previous Clinical Trials
21,530 Total Patients Enrolled
36 Trials studying Prostate Cancer
3,860 Patients Enrolled for Prostate Cancer
Prostate Cancer FoundationOTHER
40 Previous Clinical Trials
2,222 Total Patients Enrolled
24 Trials studying Prostate Cancer
1,733 Patients Enrolled for Prostate Cancer
Jeremie CalaisPrincipal InvestigatorUCLA / Jonsson Comprehensive Cancer Center
6 Previous Clinical Trials
1,253 Total Patients Enrolled
2 Trials studying Prostate Cancer
967 Patients Enrolled for Prostate Cancer

Eligibility Criteria

Age 18+ · Male Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Are researchers currently seeking out participants for this clinical experiment?

"Clinicaltrials.gov has verified that this research is recruiting participants, with the posting date of September 9th 2020 and an update on September 23rd 2022." - Anonymous Online Contributor

Unverified Answer

How many participants are presently joining the trial?

"Yes, clinicaltrials.gov affirms that this experiment is actively recruiting participants. The trial was initially made available on September 9th 2020 and has been edited most recently on the 23rd of September 2022. 30 individuals are required to be enrolled across 1 medical institution." - Anonymous Online Contributor

Unverified Answer

Has the FDA sanctioned Gallium Ga 68 FAPi-46 for medical use?

"There is only minimal data on Ga 68 FAPi-46's safety and efficacy, so it recieved a score of 1." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.